Guardant Health, Inc. (FRA:5GH)
Germany · Delayed Price · Currency is EUR | Market Cap | 20.26B +177.3% |
| Revenue (ttm) | 1.04B +42.7% |
| Net Income | -396.89M |
| EPS | -3.13 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 144.58 |
| Previous Close | 146.00 |
| Day's Range | 144.58 - 144.58 |
| 52-Week Range | 57.98 - 166.44 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial numbers in USD Financial StatementsNews
Roth starts Guardant Health with Buy on ‘premium growth’
Roth Capital analyst Max Masucci initiated coverage of Guardant Health (GH) with a Buy rating and $200 price target The firm believes the company can post “premium growth” through its…
Guardant Health initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Guardant Health (GH) with a Buy rating and $200 price target
Guardant to present 25 abstracts on liquid biopsy research portfolio at ESMO
Guardant Health (GH) announced that the company and its research collaborators will present 25 abstracts-including five rapid oral presentations-demonstrating advances in methylation-based circulating...
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—...
TwinStrand Biosciences says US PTABL rejects Guardant challenge to patent
TwinStrand Biosciences “announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (GH) challenge to a core patent underlying...
Guardant presents data from role of blood-based testing in CRC screening
Guardant Health (GH) announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer, CRC, screening an...
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the ...
Guardant Health price target raised to $200 from $185 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Guardant Health (GH) to $200 from $185 and keeps an Overweight rating on the shares as the firm refreshed…
Guardant Health price target raised to $200 from $195 at BofA
BofA raised the firm’s price target on Guardant Health (GH) to $200 from $195 and keeps a Buy rating on the shares as part of a specialty diagnostics group preview…
Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion
Guardant Health (GH) announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic to identify patients with estrogen r...
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diag...
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after ...
Guardant Health price target raised to $220 from $200 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Guardant Health (GH) to $220 from $200 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250
Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
Guardant Health reports COSMOS study published in Cancer Research Communications
Guardant Health (GH) announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study. “The study is the first pub...
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for ...
Guardant Health price target raised to $200 from $190 at Guggenheim
Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Guardant Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Q2 saw strong revenue and volume growth, with Shield now covering 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are expanding clinical use cases, while commercial wins and product innovation position the company for continued growth.
Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be cover...
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—...
Guardant Health assumed with a Buy at UBS
UBS assumed coverage of Guardant Health (GH) with a Buy rating and $225 price target Guardant Health is a core diagnostics holding, driven by durable growth across G360 liquid and…
Business Insider Names Guardant Health One of America's Most Innovative Businesses
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Business...
Guardant Health initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in testing via liquid biopsy.